MGI Tech Showcases Innovative Genomics Solutions
MGI Tech Co., Ltd. (NASDAQ: MGI) is at the forefront of genetics innovation. Recently, MGI unveiled its revolutionary multi-omics technologies at the prestigious European Society of Human Genetics (ESHG) 2025 conference. This event brought together the brightest minds in genomics, and MGI's presence shone brightly at Booth #310, where they showcased their advanced sequencing and automation platforms.
Highlights of Sequencing Innovation
One of the standout products introduced is the DNBelab C-YellowR 16. This device marks a significant advancement in single-cell automation, enabling researchers to process up to 16 single-cell samples simultaneously. This capability dramatically reduces hands-on time, enhancing overall efficiency by as much as 90% while ensuring high levels of precision and reproducibility.
The DNBelab C-YellowR 16 seamlessly transitions from cell suspension to DNA nanoballs (DNBs) ready for sequencing. Its multiple integrated modules facilitate a fully automated workflow, minimizing the need for user intervention. The system features an 8-channel pipetting module that efficiently handles plate transfer and liquid handling. Meanwhile, the Single-cell Droplet Generation module excels at cell sorting and labeling, ensuring comprehensive library preparation through high-throughput, automated processes.
Unveiling Groundbreaking Automation
This innovative setup is engineered to achieve an unattended workflow, managing everything from cell sorting through library preparation and quality control. The robust design ensures stability and reliability, addressing the challenges associated with manual single-cell operations that often struggle with complexity, throughput, and data consistency.
In addition to the C-YellowR 16, MGI introduced an advanced full-length transcriptome library preparation solution based on its proprietary Xpress Genomics technology. This allows scientists to profile full-length transcripts from as little as 10 picograms of RNA or just a handful of cells, offering crucial support for challenging research scenarios involving limited samples.
Community Engagement at ESHG
Dr. Christian Zimmerman, VP of Sales for Europe and Africa at MGI, expressed excitement about launching their latest technologies at such a pivotal event for Europe’s genomic community. He emphasized the momentum gathered around integrated multi-omics workflows, particularly highlighting both Stereo-seq and the DNBelab C-YellowR 16 as vital innovations.
This enthusiasm was palpable during a live demonstration at the MGI booth, where researchers explored new strategies aimed at increasing laboratory workflow efficiency. In parallel, MGI showcased an extensive sequencing portfolio that caters to a range of needs, from compact solutions to ultra-high-throughput capabilities, exemplified by the mid-throughput DNBSEQ-T1+, first revealed at AGBT 2025.
Corporate Symposium on Real-World Applications
A separate Corporate Satellite Symposium hosted by MGI featured discussions led by global experts on practical applications of the DNBSEQ™ platform. They highlighted various successful projects that leverage high-quality genomic data for real-world impact.
Professor J?nis Klovi?š discussed his research on building a national genomic infrastructure aligned with the European 1+ Million Genomes Initiative. His team is utilizing the DNBSEQ-T7 for whole-genome sequencing, and their efforts are vital for rare disease diagnosis and polygenic risk assessment.
Dr. Eirini Papadopoulou addressed the transformative power of next-generation sequencing (NGS) in precision oncology. She demonstrated how multigene panels are enhancing the identification of critical biomarkers for personalized treatment strategies. Meanwhile, Dr. Xin Jin shared groundbreaking findings from the China Kadoorie Biobank, showcasing how MGI's technologies enabled the sequencing of over 500,000 genomes within just six months.
Advancing Genomics in Europe
MGI's commitment to the European genomics landscape is evident through its active participation in major initiatives like the European 1+ Million Genomes Initiative and the impactful Kadoorie Biobank project. Dr. Yong Hou, MGI's General Manager for Europe and Africa, asserted that the company is focusing on supporting endeavors that are shaping the future of personalized medicine.
As MGI celebrates the 10-year anniversary of its DNBSEQ™ technology, which is trusted worldwide, the company remains excited about the prospects of reshaping genomics across Europe and Africa.
Frequently Asked Questions
What is the DNBelab C-YellowR 16?
The DNBelab C-YellowR 16 is an advanced single-cell automation system that allows processing of up to 16 single-cell samples simultaneously.
What are the benefits of the full-length transcriptome library preparation solution?
This solution enables accurate profiling from extremely low RNA inputs, essential for research scenarios with limited biological material.
How did MGI contribute to the ESHG conference?
MGI showcased innovative multi-omics technologies and engaged the scientific community through live demonstrations and a dedicated symposium.
What is the significance of the DNBSEQ-T1+ sequencer?
The DNBSEQ-T1+ represents a mid-throughput option that balances flexible sequencing capabilities in both research and clinical settings.
How is MGI impacting personalized medicine?
Through its cutting-edge technologies, MGI supports population genomics and clinical applications, contributing to advancements in personalized medicine and healthcare innovation.
